The first vaccine against the world's fastest growing mosquito-borne disease, dengue virus, has been granted marketing authorisation in Mexico. Sanofi Pasteur's Dengvaxia has been approved for prevention against four dengue virus serotypes in adults, adolescents and pre-adolescents, aged 9-45 years, by the COFEPRIS (The Federal Commission for the Protection against Sanitary Risks).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?